Life Sciences Tools & Services

IQVIA Holdings announced that its wholly owned subsidiary priced an offering of $2 billion in aggregate principal amount of senior notes due 2034. The proceeds will be used to redeem in full the issuer's Senior 5.000% Notes due 2026, repay a portion of outstanding indebtedness under its revolving credit facility, and pay related fees and expenses. The notes will bear interest at 6.375% per annum, payable semi-annually on March 15 and September 15, beginning March 15, 2027, and will mature on March 15, 2034. The issuance is expected to occur on or about September 23, 2026.

S&P Dow Jones Indices announced that Bloom Energy, Everpure, and Illumina will join the S&P 500 before trading begins Monday, September 21, replacing Molson Coors Beverage, Trade Desk, and Builders FirstSource. Bloom Energy, the largest incoming company with a market capitalization of $74 billion, supplies fuel-cell systems for data centers and industrial facilities, offering exposure to AI-driven power demand. Everpure provides data-storage systems and software, while Illumina makes gene-sequencing tools. All three stocks have gained at least 40% in 2026. Index funds and ETFs tracking the benchmark must buy the new constituents and sell the departing companies, potentially boosting volume and price moves near the effective date. A parallel S&P 100 reshuffle will add Dell, Palo Alto Networks, Arista Networks, and SanDisk, while removing Honeywell Aerospace, Nike, Simon Property Group, and Colgate-Palmolive.

Pacific Biosciences of California has seen its shares rise 11.6% since its last earnings report, outperforming the S&P 500, but the company cut its 2026 revenue guidance. In the second quarter of 2026, PacBio reported an adjusted loss per share of 14 cents, in line with estimates, while total revenues of $39 million missed the consensus by 4.2% and fell 2% year over year. The company lowered its full-year 2026 revenue outlook to $155-$165 million from a prior range of $165-$175 million, citing weaker instrument sales and a sharp revenue decline in Asia Pacific. Despite the revenue miss, consumables grew 6.3% to $20.1 million, and EMEA revenues jumped 52% to $14.4 million. Analysts have revised estimates downward by 8.33% over the past month, and the stock carries a Zacks Rank #4 (Sell).

Pacific Biosciences of California, or PacBio, lowered its 2026 revenue guidance to $155-$165 million from $165-$175 million, citing weaker instrument demand and a slower-than-expected transition to its SPRQ-Nx chemistry, even as clinical adoption grows. The company now expects cash-flow breakeven in 2028 instead of by the end of 2027, and reduced its 2026 non-GAAP gross-margin outlook to 35%-37%. In the second quarter, revenues fell 2% to $39 million, missing the Zacks Consensus Estimate by 4.2%, with instrument revenues down 9.9% to $12.8 million. However, clinical consumable shipments rose 67%, and EMEA revenues increased 52% to $14.4 million, while PacBio shipped 20 Revio systems, up from 15 a year earlier. The company expects restructuring to cut 2027 compensation-related expenses by about $15-$20 million, with additional annual savings as high-throughput platform development spending declines.

Tigermed disclosed its 2026 semi-annual report on August 29. In the first half, total operating revenue reached 3.708 billion yuan, up 14.06 percent year on year, but net profit attributable to the parent company was a loss of 413 million yuan, compared with a profit of 383 million yuan in the same period last year. Non-GAAP net profit was 278 million yuan, up 31.78 percent year on year, and net cash flow from operating activities was 426 million yuan, up 4.2 percent. During the reporting period, total non-recurring gains and losses were negative 691 million yuan, including a negative 481 million yuan change in fair value of financial assets held. As of the close on August 28, the company's price-to-earnings ratio on a trailing twelve-month basis was about 469.64 times, price-to-book ratio about 2.2 times, and price-to-sales ratio about 5.89 times.

Runda Medical released its 2026 interim report, with total operating revenue of 3.194 billion yuan and net profit attributable to the parent company of minus 87.867 million yuan, an increase of 32.7852 million yuan compared with the same period last year, narrowing the loss. Net cash inflow from operating activities was 273 million yuan, up 77.69 percent year-on-year, achieving growth for four consecutive years. The company's asset-liability ratio was 63.13 percent, and gross margin was 24.49 percent, up 3.55 percentage points from the same period last year. Diluted earnings per share were minus 0.15 yuan, and the number of shareholders was 56,200.

Tigermed released its 2026 interim report on August 28. First-half operating revenue was 3.71 billion yuan, up 14.1% year on year, but net profit attributable to the parent company was a loss of 413 million yuan, down 207.8% year on year. Second-quarter revenue was 1.91 billion yuan, up 13.0% year on year, while net profit attributable to the parent company was a loss of 462 million yuan, down 312.1% year on year. First-half net profit attributable to the parent company after deducting non-recurring items was 278 million yuan, up 31.8% year on year, and the second-quarter figure was 157 million yuan, up 45.1% year on year. As of the end of the second quarter, total assets were 27.893 billion yuan, down 1.6% from the end of the previous year, and net assets attributable to the parent company were 19.477 billion yuan, down 7.1% from the end of the previous year. The company said some small and medium-sized domestic clinical CROs have begun to scale back, industry competition is becoming more rational, supply-side optimisation is continuing, and the impact of some R&D pipelines not matching the industry's development stage has largely been cleared. The business development team has been deepening relationships with high-quality domestic clients and expanding business with large multinational pharmaceutical companies. During the reporting period, net new orders grew at an accelerating pace compared with the same period in 2025, and the average unit price of newly signed orders returned to growth. The company's market share in China's clinical outsourcing market was 10.9% in 2025, maintaining its industry-leading position.